ClinicalTrials.gg
CompletedNCT04435626FINEARTS-HFUpdated Aug 26, 2025Results posted

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

A Phase 3 interventional study of Finerenone (BAY94-8862) and Placebo in Heart Failure, sponsored by Bayer. Completed at 661 sites in 37 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-08-26.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
6,016
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing finerenone in Heart Failure — 16 open to participants now, 17 under way, 8 of them phase 3. finerenone · Heart Failure.

Enrollment
Largest of 23
6,016 · median 120
Started
2020
the only one that year
Phase 3
9 of 23
8 open now
Registered
5th of 23
by date
Lead sponsor
8 of 23
Bayer

Among the 23 studies testing finerenone in Heart Failure, this one has the largest enrollment, is the only one that started in 2020, is one of 9 in phase 3, and was the 5th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 23 studies testing finerenone in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing finerenone in Heart Failure, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of finerenone compared to placebo (a tablet without active substance) in the reduction of cardiovascular death (generally meaning death due to disease of the heart or blood vessels) and total Heart Failure (HF) events, including HF hospitalization and urgent visits for HF(generally meaning a hospital stay or urgent presentation to a healthcare unit due to worsening symptoms of heart failure) in patients suffering from HF with an ejection fraction greater than or equal to 40%. Researchers will also collect information on how much the heart disease has impact on patient's lives, change of kidney function, and how well finerenone treatment is tolerated. The study plans to enroll 6000 male and female patients of the age of 40 years and above suffering from heart failure with ejection fraction greater than or equal to 40%. Participants will take the study product as oral tablet with a dose between 0 (Placebo) 40 mg once daily. Study duration will be up to 43 months.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Heart Failure with Preserved Ejection Fraction,
  • Mineralocorticoid receptor antagonist (MRA)
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant (male or female) must be aged 40 years and older.
  • Diagnosis of heart failure with (NYHA) class II-IV, ambulatory or hospitalized primarily for heart failure.
  • On diuretic treatment for at least 30 days prior to randomization.
  • Documented (LVEF) of ≥40% measured by any modality within the last 12 months.
  • Structural heart abnormalities based on any local imaging measurement within the last 12 months, defined by at least one of the following findings: left atrial diameter (LAD) ≥3.8cm, left atrial area (LAA) ≥20cm2, left atrial volume index (LAVI) >30 mL/m2, left ventricular mass index (LVMI) ≥115 g/m2 (♂)/ 95 g/m2 (♀), septal thickness or posterior wall thickness ≥1.1 cm
  • n-terminal prohormone B-type natriuretic peptide (NT-proBNP) ≥300 pg/mL (BNP ≥100 pg/mL) in sinus rhythm and patient does not have an ongoing diagnosis of paroxysmal atrial fibrillation or NT-proBNP ≥900 pg/mL (BNP ≥300 pg/mL) in atrial fibrillation (or if atrial fibrillation status is unknown or if patient has an ongoing diagnosis of paroxysmal atrial fibrillation) for participants obtained at the following time:

    • Within 90 days prior to randomization if patient had been hospitalized for heart failure (HF) requiring initiation or change in HF therapy or if patient had an urgent visit for HF requiring intravenous (IV) diuretic therapy, both within 90 days prior to randomization OR
    • Within 30 days prior to randomization if patient has not been hospitalized for HF nor had an urgent HF visit within the past 90 days.
  • Women of can only be included in the study if a pregnancy test is negative at screening and baseline and if they agree to use adequate which is consistent with local regulations regarding the methods for contraception for those participating in clinical trials.

Exclusion criteria

Exclusion Criteria:

  • Estimated (eGFR) \<25 mL/min/1.73 m² at either screening or randomization visit.
  • Serum/plasma potassium >5.0 mmol/L at either screening or randomization visit.
  • Acute inflammatory heart disease, e.g. acute myocarditis, within 90 days prior to randomization
  • Myocardial infarction or any event which could have reduced the within 90 days prior to randomization
  • Coronary artery bypass graft surgery in the 90 days prior to randomization
  • Percutaneous coronary intervention in the 30 days prior to randomization
  • Stroke or transient ischemic cerebral attack within 90 days prior to randomization
  • Probable alternative cause of participants' HF symptoms that in the opinion of the investigator primarily accounts for patient's dyspnea such as significant pulmonary disease, anemia or obesity. Specifically, patients with the below are excluded: Severe pulmonary disease requiring home oxygen, or chronic oral therapy, History of primary pulmonary arterial hypertension, \<10 g/dl, Valvular heart disease considered by the investigator to be , (BMI) >50 kg/m2 at screening
  • Systolic blood pressure(SBP) ≥160 mmHg if not on treatment with ≥3 blood pressure lowering medications or ≥180 mmHg irrespective of treatments, on 2 consecutive measurements at least 2-minute apart, at screening or at randomization.
  • Concomitant systemic therapy with potent cytochrome P450 isoenzyme 3A4 () inhibitors (e.g. itraconazole, ritonavir, indinavir, cobicistat, clarithromycin) or moderate or potent CYP3A4 inducers, that cannot be discontinued 7 days prior to randomization and for the duration of the treatment period.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
6,016 participants (actual)

Study arms

  • Experimental
    Arm 1_BAY94-8862

    Adult patients receive BAY94-8862

    Drug: Finerenone (BAY94-8862)

  • Placebo comparator
    Arm 2_Placebo

    Adult patients receive placebo

    Other: Placebo

Interventions

  • For participants with an eGFR ≤60 mL/min/1.73 m\^2: Starting dose is 10 mg OD and maximum dose 20 mg OD. For participants with an eGFR \>60 mL/min/1.73 m\^2: Starting dose is 20 mg OD and maximum dose 40 mg OD. Finerenone is administered orally as immediate release tablets.

  • OtherPlacebo

    Placebo tablets matching BAY94-8862 are administered orally.

06

What researchers measure

Primary outcomes

  1. Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events

    Number of composite endpoint events of cardiovascular death and total (first and recurrent) heart failure (HF) events (hospitalization for heart failure or urgent HF visit) in HF patients.

    Time frame: From randomization up until the end of study, with an average study duration of 32 months

  2. Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events

    Number of participants with composite endpoint events of cardiovascular death and total (first and recurrent) heart failure (HF) events (hospitalization for heart failure or urgent HF visit) in HF patients.

    Time frame: From randomization up until the end of study, with an average study duration of 32 months

Secondary outcomes

  1. Occurrence of Total (First and Recurrent) Heart Failure Events

    Number of total (first and recurrent) heart failure events.

    Time frame: From randomization up until the end of study, with an average study duration of 32 months

  2. Occurrence of Total (First and Recurrent) Heart Failure Events

    Number of participants with total (first and recurrent) heart failure events.

    Time frame: From randomization up until the end of study, with an average study duration of 32 months

  3. Change From Baseline in Total Symptom Score (TSS) of the Kansas City Cardiomyopathy Questionnaire (KCCQ)

    The Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) is ranged from 0 to 100. A higher score (closer to 100) reflects fewer symptoms, indicating better heart failure symptom status. For the change from baseline the combined and averaged result across the entire time frame is reported.

    Time frame: From baseline to Month 6, 9 and 12

  4. Proportion of Participants Who Showed Improvement in NHYA Class

    The New York Heart Association (NYHA) Functional Classification is a simple scale that classifies patients with heart failure based on the severity of their symptoms and how those symptoms affect their physical activity, which ranges from Class I to Class IV, a lower class number is indicative of a better condition. A patient was considered as having improved in NYHA class, if the NYHA class at Month 12 is at least one category improved compared to the baseline visit.

    Time frame: from baseline to Month 12

  5. First Occurrence of Renal Composite Events

    Number of participants with renal composite events encompassing the components sustained decrease in eGFR ≥50% relative to baseline over at least 4 weeks, sustained eGFR decline to \<15 mL/min/1.73 m2 over at least 4 weeks, initiation of chronic dialysis and renal transplantation.

    Time frame: From randomization up to end of study visit, with an average study duration of 32 months

  6. Occurence of All-cause Mortality (Full Analysis Set)

    Number of participants with death due to any cause were reported as descriptive result. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table.

    Time frame: From randomization until end of study, with an average of 32 months

07

Results

Posted Aug 26, 2025

Participant flow

Study was conducted at multiple centers in 37 countries/regions between 14-Sep-2020 (first participant first visit) and 14-Jun-2024 (last participant last visit).

Participant flow — Overall Study
MilestoneFinerenone (BAY94-8862)Placebo
Started30113005
Valid for fas30032998
Completed29962986
Not completed1519
Withdrew: Lost to follow-up15
Withdrew: Withdrawal by subject67
Withdrew: Major gcp violations87

Outcome measures

PrimaryOccurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events

Number of composite endpoint events of cardiovascular death and total (first and recurrent) heart failure (HF) events (hospitalization for heart failure or urgent HF visit) in HF patients.

Time frame:
From randomization up until the end of study, with an average study duration of 32 months
Reported as:
Number · events
Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events
eventsFinerenone (BAY94-8862)Placebo
Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events10831283
Statistical analysis
  • Finerenone (BAY94-8862) vs Placebo · stratified Andersen-Gill model · p = 0.0072 (Two-sided p-value; p-value threshold =0.04967;) · Rate ratio: 0.84 · 95% CI 0.74 to 0.95stratified Andersen-Gill model with robust sandwich estimate for the covariance matrix of recurrent events
PrimaryOccurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events

Number of participants with composite endpoint events of cardiovascular death and total (first and recurrent) heart failure (HF) events (hospitalization for heart failure or urgent HF visit) in HF patients.

Time frame:
From randomization up until the end of study, with an average study duration of 32 months
Reported as:
Count of participants · Participants
Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events
ParticipantsFinerenone (BAY94-8862)Placebo
Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events624719
SecondaryOccurrence of Total (First and Recurrent) Heart Failure Events

Number of total (first and recurrent) heart failure events.

Time frame:
From randomization up until the end of study, with an average study duration of 32 months
Reported as:
Number · events
Occurrence of Total (First and Recurrent) Heart Failure Events
eventsFinerenone (BAY94-8862)Placebo
Occurrence of Total (First and Recurrent) Heart Failure Events8421024
Statistical analysis
  • Finerenone (BAY94-8862) vs Placebo · Stratified Andersen-Gill model · p = 0.0062 (Two-sided p-value; p-value threshold=0.04967;) · Rate ratio: 0.82 · 95% CI 0.71 to 0.94stratified Andersen-Gill model with robust sandwich estimate for the covariance matrix of recurrent events
SecondaryOccurrence of Total (First and Recurrent) Heart Failure Events

Number of participants with total (first and recurrent) heart failure events.

Time frame:
From randomization up until the end of study, with an average study duration of 32 months
Reported as:
Count of participants · Participants
Occurrence of Total (First and Recurrent) Heart Failure Events
ParticipantsFinerenone (BAY94-8862)Placebo
Occurrence of Total (First and Recurrent) Heart Failure Events479573
SecondaryChange From Baseline in Total Symptom Score (TSS) of the Kansas City Cardiomyopathy Questionnaire (KCCQ)

The Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) is ranged from 0 to 100. A higher score (closer to 100) reflects fewer symptoms, indicating better heart failure symptom status. For the change from baseline the combined and averaged result across the entire time frame is reported.

Time frame:
From baseline to Month 6, 9 and 12
Reported as:
Least squares mean · score on scale
Change From Baseline in Total Symptom Score (TSS) of the Kansas City Cardiomyopathy Questionnaire (KCCQ)
score on scaleFinerenone (BAY94-8862)Placebo
Change From Baseline in Total Symptom Score (TSS) of the Kansas City Cardiomyopathy Questionnaire (KCCQ)7.99 (7.37 to 8.62)6.43 (5.79 to 7.07)
Statistical analysis
  • Finerenone (BAY94-8862) vs Placebo · Mixed Models Analysis · p = <.0001 (Two-sided p-value;) · Difference in ls mean: 1.56 · 95% CI 0.79 to 2.34The analysis was performed using mixed-effects model for repeated measures (MMRM)
SecondaryProportion of Participants Who Showed Improvement in NHYA Class

The New York Heart Association (NYHA) Functional Classification is a simple scale that classifies patients with heart failure based on the severity of their symptoms and how those symptoms affect their physical activity, which ranges from Class I to Class IV, a lower class number is indicative of a better condition. A patient was considered as having improved in NYHA class, if the NYHA class at Month 12 is at least one category improved compared to the baseline visit.

Time frame:
from baseline to Month 12
Reported as:
Number · Estimated proportion
Proportion of Participants Who Showed Improvement in NHYA Class
Estimated proportionFinerenone (BAY94-8862)Placebo
Proportion of Participants Who Showed Improvement in NHYA Class0.179 (0.163 to 0.195)0.178 (0.162 to 0.194)
Statistical analysis
  • Finerenone (BAY94-8862) vs Placebo · Regression, Logistic · p = 0.9295 (Two-sided p-value) · Odds ratio (or): 1.01 · 95% CI 0.88 to 1.15
SecondaryFirst Occurrence of Renal Composite Events

Number of participants with renal composite events encompassing the components sustained decrease in eGFR ≥50% relative to baseline over at least 4 weeks, sustained eGFR decline to \<15 mL/min/1.73 m2 over at least 4 weeks, initiation of chronic dialysis and renal transplantation.

Time frame:
From randomization up to end of study visit, with an average study duration of 32 months
Reported as:
Count of participants · Participants
First Occurrence of Renal Composite Events
ParticipantsFinerenone (BAY94-8862)Placebo
First Occurrence of Renal Composite Events7555
Statistical analysis
  • Finerenone (BAY94-8862) vs Placebo · Stratified log-rank test · p = 0.1071 (two-sided p-value) · Cause-specific hazard ratio: 1.33 · 95% CI 0.94 to 1.89stratified Cox proportional hazards model
SecondaryOccurence of All-cause Mortality (Full Analysis Set)

Number of participants with death due to any cause were reported as descriptive result. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table.

Time frame:
From randomization until end of study, with an average of 32 months
Reported as:
Count of participants · Participants
Occurence of All-cause Mortality (Full Analysis Set)
ParticipantsFinerenone (BAY94-8862)Placebo
Occurence of All-cause Mortality (Full Analysis Set)491522
Statistical analysis
  • Finerenone (BAY94-8862) vs Placebo · stratified log-rank · p = 0.2794 (two-sided p-value) · Cause-specific hazard ratio: 0.93 · 95% CI 0.83 to 1.06stratified Cox proportional hazards model

Adverse events

Collected over Treatment emergent adverse events (TEAEs) are considered from the start of study intervention up to 3 days after the last study intervention administration, with an average treatment duration of 28 months. In contrast, numbers for all-cause mortality listed below consider all deaths after randomization over the entire average study duration of 32 months, independent of treatment and including deaths which occurred after the end of study visit in the 4-week follow-up period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Finerenone (BAY94-8862)494/2,993 (16.5%)1,157/2,993 (38.7%)1,317/2,993 (44%)
Placebo528/2,993 (17.6%)1,213/2,993 (40.5%)1,228/2,993 (41%)
Never Received Treatment3/15 (20%)0/15 (0%)0/15 (0%)
Most frequent serious events
Showing 10 of 925
Most frequent serious events
EventFinerenone (BAY94-8862)PlaceboNever Received Treatment
PneumoniaInfections and infestations87/2993110/29930/15
Atrial fibrillationCardiac disorders77/299373/29930/15
COVID-19Infections and infestations69/299371/29930/15
Acute kidney injuryRenal and urinary disorders54/299328/29930/15
DeathGeneral disorders29/299352/29930/15
Angina unstableCardiac disorders38/299336/29930/15
AnaemiaBlood and lymphatic system disorders34/299331/29930/15
COVID-19 pneumoniaInfections and infestations28/299330/29930/15
Urinary tract infectionInfections and infestations29/299326/29930/15
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders18/299327/29930/15
Most frequent other events
Showing 10 of 12
Most frequent other events
EventFinerenone (BAY94-8862)PlaceboNever Received Treatment
COVID-19Infections and infestations292/2993297/29930/15
HyperkalaemiaMetabolism and nutrition disorders252/2993107/29930/15
HypotensionVascular disorders210/2993128/29930/15
HypokalaemiaMetabolism and nutrition disorders88/2993196/29930/15
Renal impairmentRenal and urinary disorders193/2993110/29930/15
HypertensionVascular disorders103/2993179/29930/15
DizzinessNervous system disorders170/2993137/29930/15
AnaemiaBlood and lymphatic system disorders169/2993162/29930/15
Cardiac failureCardiac disorders116/2993168/29930/15
DiarrhoeaGastrointestinal disorders167/2993129/29930/15

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Finerenone (BAY94-8862)PlaceboTotal
Mean71.94 ± 9.6072.04 ± 9.6971.99 ± 9.65
Sex: Female, Male
Sex: Female, Male(Participants)Finerenone (BAY94-8862)PlaceboTotal
Female135513772732
Male164816213269
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Finerenone (BAY94-8862)PlaceboTotal
American Indian or Alaska Native7574149
Asian497499996
Native Hawaiian or Other Pacific Islander101
Black or African American493988
White236623694735
More than one race7815
Unknown or Not Reported8917
NYHA class
NYHA class(Participants)Finerenone (BAY94-8862)PlaceboTotal
NYHA class II208120654146
NYHA class III9039101813
NYHA class IV182341
missing101
Baseline LVEF
Baseline LVEF(percentage of ejection fraction)Finerenone (BAY94-8862)PlaceboTotal
Mean52.64 ± 7.8252.49 ± 7.8152.56 ± 7.81
08

Study locations

661 sites
  • Cardiology, PC
    Birmingham, Alabama 35211, United States
  • Eastern Shore Research Institute, LLC | Fairhope, AL
    Fairhope, Alabama 36532, United States
  • Mobile Heart Specialists - Providence
    Mobile, Alabama 36608, United States
  • University of Arizona Clinical and Translational Sciences Research Center
    Tucson, Arizona 85724, United States
  • Heart Clinic Arkansas
    Little Rock, Arkansas 72205, United States
  • WestSide Medical
    Beverly Hills, California 90211, United States
  • CA Heart and Vein Specialists
    Huntington Beach, California 92648, United States
  • UCI Medical Center - Neurology
    Orange, California 92868, United States
  • Sutter Medical Center - Cardiology
    Sacramento, California 95816, United States
  • NorthBay Clinical Research, LLC | Santa Rosa, CA
    Santa Rosa, California 95405, United States
  • The Lundquist Institute - Gynecology
    Torrance, California 90502, United States
  • Blue Coast Research Center, LLC
    Vista, California 92081, United States
  • Interventional Cardio Medical- DCT Department
    West Hills, California 91307, United States
  • Interventional Cardiology Medical Group | West Hills, CA
    West Hills, California 91307, United States
  • VA Eastern Colorado Health Care System
    Aurora, Colorado 80045, United States
  • Colorado Springs Cardiology - Woodmen Medical Plaza
    Colorado Springs, Colorado 80923, United States
  • South Denver Cardiology Associates, PC
    Littleton, Colorado 80120, United States
  • Cardiovascular & Vein Center of Florida | Bradenton, FL
    Bradenton, Florida 34209, United States
  • Nova Clinical Research - Blake Medical Center
    Bradenton, Florida 34209, United States
  • Cardiology Associates Research Company
    Daytona Beach, Florida 32117, United States
  • North Florida Foundation for Research and Education - Clinical Trial Center
    Gainesville, Florida 32608, United States
  • LifeSpring Research Foundation, LLC
    Miami, Florida 33130, United States
  • Southwest Florida Research | Naples, FL
    Naples, Florida 34102-8143, United States
  • East Coast Institute for Research | St. Augustine, FL
    Saint Augustine, Florida 32086, United States
  • Cardiology Partners Clinical Research Institute | Wellington Office
    Wellington, Florida 33449, United States
  • Centricity Research at Talbotton
    Columbus, Georgia 31904, United States
  • Atlanta Heart Specialists - Tucker
    Tucker, Georgia 30084, United States
  • Advocate Illinois Masonic Medical Center - Cardiology
    Chicago, Illinois 60657, United States
  • Advocate Good Samaritan Hospital - Cardiology
    Downers Grove, Illinois 60515, United States
  • Advocate Condell Medical Center
    Libertyville, Illinois 60048, United States
  • Edward Hospital - Main Campus - Cardiology
    Naperville, Illinois 60540, United States
  • Captain James A. Lovell Federal Health Care Center
    North Chicago, Illinois 60064, United States
  • Carle Health Methodist Hospital - Cardiology
    Peoria, Illinois 61603, United States
  • Midwest Cardiovascular Research and Education Foundation | Elkhart, IN
    Elkhart, Indiana 46514, United States
  • Reid Physicians Associates - Cardiology Department
    Richmond, Indiana 47374, United States
  • Kansas Nephrology Research Institute
    Wichita, Kansas 67214, United States
  • Baptist Health Paducah - Cardiology
    Paducah, Kentucky 42003, United States
  • Cardiovascular Associates Research, LLC
    Covington, Louisiana 70433, United States
  • Heart Clinic of Hammond
    Hammond, Louisiana 70403, United States
  • Louisiana Heart Center - Slidell
    Slidell, Louisiana 70458, United States
  • Southern Clinical Research, LLC
    Zachary, Louisiana 70791, United States
  • MaineHealth Cardiology - Scarborough
    Scarborough, Maine 04039, United States
  • Johns Hopkins Hospital - Cardiology
    Baltimore, Maryland 21287, United States
  • Suburban Hospital - Cardiology
    Bethesda, Maryland 20814, United States
  • Cardiovascular Specialists of Central Maryland, PA
    Columbia, Maryland 21044, United States
  • Henry Ford Hospital - OB/GYN
    Detroit, Michigan 48202, United States
  • AA Medical Research Center | Flint, MI
    Flint, Michigan 48504, United States
  • M Health Fairview Heart Clinic - Maplewood
    Maplewood, Minnesota 55109, United States
  • M Health Fairview Heart Clinic - Fulton
    Minneapolis, Minnesota 55455, United States
  • St. Cloud Hospital
    Saint Cloud, Minnesota 56303, United States
  • Baptist Heart -Cardiology - DCT Dept
    Jackson, Mississippi 39202, United States
  • University Hospital - UMMC - Nephrology
    Jackson, Mississippi 39216, United States
  • Harry S Truman Memorial Veterans Hospital - Cardiology
    Columbia, Missouri 65201, United States
  • Clinical Research Consultants
    Kansas City, Missouri 64111, United States
  • Saint Luke's Mid America Heart Institute
    Kansas City, Missouri 64111, United States
  • Mercy Hospital Springfield - Cardiology
    Springfield, Missouri 65804, United States
  • Logan Health Research
    Kalispell, Montana 59901, United States
  • CHI Health Clinic Heart Institute - Grand Island
    Grand Island, Nebraska 68803, United States
  • CHI Health Nebraska Heart
    Lincoln, Nebraska 68526, United States
  • Advanced Heart Care, LLC | Bridgewater, NJ
    Bridgewater, New Jersey 08807, United States
  • NJ Heart | Linden, NJ
    Linden, New Jersey 07036, United States
  • Garden State Heart Care
    Manalapan, New Jersey 07726, United States
  • Nuvance Health - The Heart Center
    Poughkeepsie, New York 12601, United States
  • Division of Cardiovascular Research at Peconic Bay Medical Center
    Riverhead, New York 11901, United States
  • Laurelton Heart Specialists
    Rosedale, New York 11422, United States
  • Saratoga Clinical Research, LLC
    Saratoga Springs, New York 12866, United States
  • Cardiac Care & Vascular Medicine
    The Bronx, New York 10469, United States
  • Northwell Health Physician Partners Cardiology at Valley Stream
    Valley Stream, New York 11580, United States
  • Kernodle Clinic West
    Burlington, North Carolina 27215, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27514, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27157, United States
  • Kettering Health Network | Research Institute
    Kettering, Ohio 45429, United States
  • Rama Research LLC | Marion, OH
    Marion, Ohio 43302-6774, United States
  • Mercy Health - St. Elizabeth Youngstown Hospital
    Youngstown, Ohio 44501, United States
  • South Oklahoma Heart Research, LLC
    Oklahoma City, Oklahoma 73135, United States
  • Capital Area Research | Camp Hill, PA
    Camp Hill, Pennsylvania 17011, United States
  • Doylestown Health Cardiology - DCA
    Doylestown, Pennsylvania 18901, United States
  • Kent Hospital
    Warwick, Rhode Island 02886, United States
  • Trident Cardiology Associates, PA
    Ladson, South Carolina 29456, United States
  • Carolina Heart Specialists | Lancaster, SC
    Lancaster, South Carolina 29720, United States
  • Monument Health Clinical Research
    Rapid City, South Dakota 57701, United States
  • Sanford USD Medical Center - Cardiology
    Sioux Falls, South Dakota 57105, United States
  • The Stern Cardiovascular Foundation - Germantown, TN
    Germantown, Tennessee 38138, United States
  • Apex Research Foundation, LLC. | Jackson, TN
    Jackson, Tennessee 38301, United States
  • Lt. Col. Luke Weathers, Jr. VA Medical Center - Cardiology
    Memphis, Tennessee 38105, United States
  • Cardiovascular Research of Knoxville
    Powell, Tennessee 37849, United States
  • Ascension Seton Heart Specialty Care and Transplant Center
    Austin, Texas 78705, United States
  • Texas Health & Vascular Specialists - Dallas
    Dallas, Texas 75231, United States
  • Southwest Family Medicine Associates | Dallas, TX
    Dallas, Texas 75235, United States
  • Texas Health Family Care - W Vickery Blvd
    Fort Worth, Texas 76107, United States
  • University of Texas Medical Branch at Galveston
    Galveston, Texas 77555, United States
  • Houston Heart & Vascular Associates
    Humble, Texas 77338, United States
  • South Texas Cardiovascular Consultants, PLLC / Kerrville, TX
    Kerrville, Texas 78028, United States
  • North Dallas Research Associates
    McKinney, Texas 75069, United States
  • ClinRx Research, LLC
    Plano, Texas 75024, United States
  • South Texas Cardiovascular Consultants - San Antonio
    San Antonio, Texas 78201, United States
  • Clinical Advancement Center, PLLC
    San Antonio, Texas 78212, United States
  • Northwest Houston Clinical Research - Tomball
    Tomball, Texas 77375, United States
  • University of Utah Clinical Neurosciences Center
    Salt Lake City, Utah 84312, United States
  • Inova Cardiology- Fairfax
    Fairfax, Virginia 22031, United States

Showing the first 100 of 661 sites across 37 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bhatt AS, Chatur S, Claggett BL, Lay-Flurrie J, Viswanathan P, Vardeny O, Kosiborod MN, Sharma K, Solomon SD, Vaduganathan M. Gamified Behavioral Science Intervention to Enhance Trial Enrollment: An Embedded Study Within the FINEARTS-HF Trial. JACC Heart Fail. 2024 Nov;12(11):1939-1941. doi: 10.1016/j.jchf.2024.05.002. Epub 2024 May 11. No abstract available. PubMed 38944793 ↗
  • Jhund PS, Talebi A, Henderson AD, Claggett BL, Vaduganathan M, Desai AS, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Solomon SD, McMurray JJV. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet. 2024 Sep 21;404(10458):1119-1131. doi: 10.1016/S0140-6736(24)01733-1. Epub 2024 Sep 1. PubMed 39232490 ↗
  • Kondo T, Henderson AD, Docherty KF, Jhund PS, Vaduganathan M, Solomon SD, McMurray JJV. Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF? J Am Coll Cardiol. 2024 Nov 26;84(22):2233-2240. doi: 10.1016/j.jacc.2024.08.033. Epub 2024 Sep 1. PubMed 39217560 ↗
  • Ostrominski JW, Aggarwal R, Claggett BL, Kulac IJ, Desai AS, Jhund PS, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Lay-Flurrie J, Viswanathan P, McMurray JJV, Solomon SD, Vaduganathan M. Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to U.S. Adults With Heart Failure. J Card Fail. 2024 Sep;30(9):1170-1174. doi: 10.1016/j.cardfail.2024.04.015. Epub 2024 May 11. No abstract available. PubMed 38740173 ↗
  • Ostrominski JW, Claggett BL, Miao ZM, Mc Causland FR, Anand IS, Desai AS, Jhund PS, Lam CSP, Pfeffer MA, Pitt B, Zannad F, Zile MR, Bomfim Wirtz A, Lay-Flurrie J, Viswanathan P, McMurray JJV, Solomon SD, Vaduganathan M. Cardiovascular-Kidney-Metabolic Overlap in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis. J Am Coll Cardiol. 2024 Jul 9;84(2):223-228. doi: 10.1016/j.jacc.2024.05.005. Epub 2024 May 12. No abstract available. PubMed 38744407 ↗
  • Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Henderson AD, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, Atherton JJ, Bauersachs J, Chang-Sheng M, Chiang CE, Chioncel O, Chopra V, Comin-Colet J, Filippatos G, Fonseca C, Gajos G, Goland S, Goncalvesova E, Kang S, Katova T, Kosiborod MN, Latkovskis G, Lee AP, Linssen GCM, Llamas-Esperon G, Mareev V, Martinez FA, Melenovsky V, Merkely B, Nodari S, Petrie MC, Saldarriaga CI, Saraiva JFK, Sato N, Schou M, Sharma K, Troughton R, Udell JA, Ukkonen H, Vardeny O, Verma S, von Lewinski D, Voronkov L, Yilmaz MB, Zieroth S, Lay-Flurrie J, van Gameren I, Amarante F, Kolkhof P, Viswanathan P; FINEARTS-HF Committees and Investigators. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024 Oct 24;391(16):1475-1485. doi: 10.1056/NEJMoa2407107. Epub 2024 Sep 1. PubMed 39225278 ↗
  • Solomon SD, Ostrominski JW, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, Atherton JJ, Bauersachs J, Ma CS, Chiang CE, Chioncel O, Chopra V, Comin-Colet J, Filippatos G, Fonseca C, Gajos G, Goland S, Goncalvesova E, Kang SM, Katova T, Kosiborod MN, Latkovskis G, Lee AP, Linssen GCM, Llamas-Esperon G, Mareev V, Martinez FA, Melenovsky V, Merkely B, Nodari S, Petrie MC, Saldarriaga CI, Saraiva JFK, Sato N, Schou M, Sharma K, Troughton R, Udell JA, Ukkonen H, Vardeny O, Verma S, von Lewinski D, Voronkov LG, Yilmaz MB, Zieroth S, Lay-Flurrie J, van Gameren I, Amarante F, Viswanathan P, McMurray JJV. Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial. Eur J Heart Fail. 2024 Jun;26(6):1334-1346. doi: 10.1002/ejhf.3266. Epub 2024 May 11. PubMed 38733212 ↗
  • Vaduganathan M, Claggett BL, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Desai AS, Jhund PS, Viswanathan P, Bomfim Wirtz A, Schloemer P, Lay-Flurrie J, McMurray JJV, Solomon SD. Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial. Eur J Heart Fail. 2024 Jun;26(6):1324-1333. doi: 10.1002/ejhf.3253. Epub 2024 May 14. PubMed 38742248 ↗
  • Vaduganathan M, Filippatos G, Claggett BL, Desai AS, Jhund PS, Henderson A, Brinker M, Kolkhof P, Schloemer P, Lay-Flurrie J, Viswanathan P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Rossing P, Ruilope LM, Anker SD, Pitt B, Agarwal R, McMurray JJV, Solomon SD. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med. 2024 Dec;30(12):3758-3764. doi: 10.1038/s41591-024-03264-4. Epub 2024 Sep 1. PubMed 39218030 ↗
  • Vaduganathan M, Neuen BL, McCausland F, Jhund PS, Docherty KF, McMurray JJV, Solomon SD. Why Has it Been Challenging to Modify Kidney Disease Progression in Patients With Heart Failure? J Am Coll Cardiol. 2024 Nov 26;84(22):2241-2245. doi: 10.1016/j.jacc.2024.08.034. Epub 2024 Sep 1. No abstract available. PubMed 39217561 ↗
  • Boettger P, Sedighi J, Sohns C, Bauersachs J, Assmus B, Sossalla S. Cost-effectiveness of finerenone in heart failure with mildly reduced or preserved ejection fraction - Insights from FINEARTS-HF. Eur J Heart Fail. 2026 May 24:xuag167. doi: 10.1093/ejhf/xuag167. Online ahead of print. PubMed 42178507 ↗
  • Bains M, Butt JH, Ostrominski JW, Pabon Porras MA, Humphreys-Davies L. Treatment with finerenone in people with heart failure and mildly reduced or preserved ejection fraction: a plain language review. Future Cardiol. 2026 Apr;22(4):323-351. doi: 10.1080/14796678.2026.2650667. Epub 2026 Apr 28. PubMed 42047456 ↗
  • Hamatani Y, Claggett BL, Desai AS, Lewis EF, Jhund PS, Lam CSP, Martinez FA, Zannad F, Pfeffer MA, McMurray JJV, Solomon SD, Vaduganathan M. Interchangeability of the KCCQ-12 and KCCQ-23 Across >18,000 Participants Enrolled in 4 Large-Scale Trials of Heart Failure. J Am Coll Cardiol. 2026 Jun 30;87(25):3559-3569. doi: 10.1016/j.jacc.2026.03.026. Epub 2026 Mar 16. PubMed 41995644 ↗
  • Lu H, Kosztin A, Claggett BL, Foa A, Pabon MA, Desai AS, Jhund PS, Henderson AD, Merkely B, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Amarante F, Saarinen R, De Sanctis Y, Glasauer A, McMurray JJV, Vaduganathan M, Solomon SD. Biomarker, Functional Status, and Quality-of-Life Trajectories Before Modes of Death in Heart Failure: Post Hoc Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2026 Jun 1;11(6):574-582. doi: 10.1001/jamacardio.2026.0682. PubMed 41903171 ↗
  • Chimura M, McDowell K, Jhund PS, Henderson AD, Claggett BL, Desai AS, Brinker M, Lay-Flurrie J, Glasauer A, Goea L, Berger M, Lam CSP, Senni M, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. EMPEROR-Preserved Risk Model and Outcomes in the FINEARTS-HF Trial: A Prespecified Secondary Analysis of FINEARTS-HF. JAMA Cardiol. 2026 May 1;11(5):416-426. doi: 10.1001/jamacardio.2026.1049. PubMed 41903165 ↗
  • Hamatani Y, Peikert A, Claggett BL, Desai AS, Jhund PS, Henderson AD, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Lay-Flurrie J, Lage A, Hofmeister L, McMurray JJV, Solomon SD, Vaduganathan M. Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy Questionnaire. Eur J Heart Fail. 2026 Mar 12:xuag062. doi: 10.1093/ejhf/xuag062. Online ahead of print. PubMed 41817207 ↗
  • Chimura M, Jhund PS, Henderson AD, Claggett BL, Desai AS, Lay-Flurrie J, Scalise A, Rohwedder K, Lam CSP, Senni M, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Efficacy of finerenone in patients with heart failure and mildly reduced or preserved ejection fraction: a prespecified analysis of heart rate and heart rhythm in the FINEARTS-HF trial. Eur J Heart Fail. 2026 May 2;28(1):26-38. doi: 10.1093/ejhf/xuag008. PubMed 41771075 ↗
  • Henderson AD, Docherty KF, Talebi A, Kondo T, Petrie MC, Claggett BL, Desai AS, Vaduganathan M, Atherton JJ, Bauersachs J, Schou M, Verma S, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Brinker M, Amarante F, Rohwedder K, Lay-Flurrie J, Solomon SD, McMurray JJV, Jhund PS. A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HF. Eur Heart J Cardiovasc Pharmacother. 2026 May 19;12(3):176-185. doi: 10.1093/ehjcvp/pvag010. PubMed 41697954 ↗
  • Chimura M, Henderson AD, Jhund PS, Claggett BL, Desai AS, Filippatos G, Gajos G, Brinker M, Amarante F, Lay-Flurrie J, Rohwedder K, Lam CSP, Sato N, Senni M, Voors AA, Zannad F, Yilmaz MB, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Efficacy and Safety of the Kidney Function-Based Finerenone Dosing Strategy Used in FINEARTS-HF. JACC Heart Fail. 2026 Jun;14(6):102938. doi: 10.1016/j.jchf.2026.102938. Epub 2026 Feb 4. PubMed 41642173 ↗
  • Butt JH, Henderson AD, Jhund PS, Claggett BL, Desai AS, Borentain M, Rohwedder K, Dayoub R, De Sanctis Y, Lam CSP, Senni M, Shah SJ, Voors AA, Bauersachs J, Fonseca C, Linssen GCM, Petrie MC, Schou M, Verma S, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF. Circ Heart Fail. 2026 Feb;19(2):e013201. doi: 10.1161/CIRCHEARTFAILURE.125.013201. Epub 2026 Jan 29. PubMed 41608790 ↗
  • Foa A, Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Henderson AD, Chatur S, Amarante F, Hofmeister L, Horvat-Broecker A, Kuhls S, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, McMurray JJV, Solomon SD. Finerenone-Related Risk of Hypotension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC Heart Fail. 2026 Apr;14(4):102779. doi: 10.1016/j.jchf.2025.102779. Epub 2025 Dec 9. PubMed 41364043 ↗
  • Ostrominski JW, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Rohwedder K, Brinker M, Schloemer P, McMurray JJV, Solomon SD, Vaduganathan M. Finerenone according to insulin resistance in heart failure: Insights from the FINEARTS-HF trial. Eur J Heart Fail. 2025 Dec;27(12):2788-2799. doi: 10.1002/ejhf.70034. Epub 2025 Sep 8. PubMed 40916719 ↗
  • Lu H, Claggett BL, Vaduganathan M, Desai AS, Jhund PS, Voors AA, Senni M, Zannad F, Pitt B, Shah SJ, Lam CSP, Scheerer MF, Scalise A, Mueller K, Berger M, Goea L, McMurray JJV, Solomon SD. Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC Heart Fail. 2025 Oct;13(10):102590. doi: 10.1016/j.jchf.2025.102590. Epub 2025 Aug 25. PubMed 40857999 ↗
  • Chimura M, Jhund PS, Henderson AD, Yang M, Claggett BL, Desai AS, Rohwedder K, Lage A, Scalise A, Mueller K, Schou M, Lam CSP, Senni M, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Efficacy and Tolerability of Finerenone According to the Use and Dosage of Diuretics: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Aug 13;10(10):979-89. doi: 10.1001/jamacardio.2025.2551. Online ahead of print. PubMed 40802267 ↗
  • Butt JH, Jhund PS, Henderson AD, Claggett BL, Chiang CE, Linssen GCM, Saldarriaga CI, Saraiva JFK, Sato N, Schou M, von Lewinski D, Lay-Flurrie J, Scalise A, Rohwedder K, Desai AS, Lam CSP, Senni M, Shah SJ, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Aug 1;10(8):829-840. doi: 10.1001/jamacardio.2025.1775. PubMed 40531488 ↗
  • Ferreira JP, Zannad F. Screening for Undiagnosed Heart Failure: A Viewpoint. J Card Fail. 2025 Aug;31(8):1339-1344. doi: 10.1016/j.cardfail.2025.04.016. Epub 2025 May 23. PubMed 40414280 ↗
  • Pabon MA, Vardeny O, Vaduganathan M, Desai AS, Claggett BL, Kulac IJ, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Saldarriaga CI, Petrie MC, Merkely B, Borentain M, Mueller K, Viswanathan P, Amarante F, Morris A, McMurray JJV, Solomon SD. Finerenone in Heart Failure With Improved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Jul 1;10(7):740-745. doi: 10.1001/jamacardio.2025.1101. PubMed 40397470 ↗
  • Chimura M, Yang M, Henderson AD, Jhund PS, Docherty KF, Claggett BL, Desai AS, Filippatos G, Gajos G, Mueller K, Glasauer A, Rohwedder K, Viswanathan P, Lam CSP, Sato N, Senni M, Voors AA, Zannad F, Yilmaz MB, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV; FINEARTS-HF Committees and Investigators. Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial. Eur J Heart Fail. 2025 Nov;27(11):2301-2312. doi: 10.1002/ejhf.3682. Epub 2025 May 16. PubMed 40377177 ↗
  • Kondo T, Jhund PS, Henderson AD, Claggett BL, Desai AS, Brinker M, Lay-Flurrie J, Schloemer P, Viswanathan P, Amarante F, Chiang CE, Filippatos G, Lam CSP, Petrie MC, Senni M, Schou M, Verma S, Voors AA, von Lewinski D, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HF. Eur J Heart Fail. 2025 Aug;27(8):1459-1471. doi: 10.1002/ejhf.3669. Epub 2025 Apr 29. PubMed 40300840 ↗
  • Ostrominski JW, Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Borentian M, Rohwedder K, Lay-Flurrie J, Lavagnino MA, McMurray JJV, Solomon SD. Finerenone and NYHA Functional Class in Heart Failure: The FINEARTS-HF Trial. JACC Heart Fail. 2026 Jan;14(1):102440. doi: 10.1016/j.jchf.2025.03.007. Epub 2025 Apr 2. PubMed 40232214 ↗
  • Butt JH, Jhund PS, Henderson AD, Claggett BL, Desai AS, Lam CSP, Mueller K, Scheerer MF, Viswanathan P, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial. Eur J Heart Fail. 2025 Aug;27(8):1444-1458. doi: 10.1002/ejhf.3661. Epub 2025 Apr 13. PubMed 40222820 ↗
  • Ostrominski JW, Mc Causland FR, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Schloemer P, Brinker M, Scheerer MF, McMurray JJV, Solomon SD, Vaduganathan M. Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF Trial. JACC Heart Fail. 2026 Jan;14(1):102439. doi: 10.1016/j.jchf.2025.03.006. Epub 2025 Apr 2. PubMed 40208137 ↗
  • Desai AS, Jhund PS, Vaduganathan M, Claggett BL, Cunningham JW, Pabon MA, Lam CSP, Senni M, Shah S, Voors AA, Zannad F, Pitt B, Amarante F, Lay-Flurrie J, Scheerer MF, Lage A, McMurray JJV, Solomon SD. Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Jul 1;10(7):678-685. doi: 10.1001/jamacardio.2025.0860. PubMed 40159247 ↗
  • Matsumoto S, Henderson AD, Jhund PS, Bauersachs J, Chioncel O, Claggett BL, Comin-Colet J, Desai AS, Filippatos G, Lam CSP, Pitt B, Scheerer MF, Lay-Flurrie J, Amarante F, Brinker M, Schou M, Senni M, Shah SJ, Voors AA, Zannad F, Zieroth S, Vaduganathan M, Solomon SD, McMurray JJV. Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Jul 1;10(7):696-707. doi: 10.1001/jamacardio.2025.0848. PubMed 40156827 ↗
  • McDowell K, Docherty KF, Campbell RT, Henderson AD, Jhund PS, Claggett BL, Desai AS, Lay-Flurrie J, Hofmeister L, Scalise A, Lam CSP, Petrie MC, Schou M, Senni M, Shah SJ, Udell JA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF. JAMA Cardiol. 2025 Jun 1;10(6):535-544. doi: 10.1001/jamacardio.2025.0025. PubMed 40042880 ↗
  • Cunningham JW, Chatur S, Claggett BL, Vaduganathan M, Desai AS, Jhund PS, Llamas Esperon G, Lam CSP, Sato N, Senni M, Shah S, Voors A, Zannad F, Pitt B, Zieroth S, Brinker M, Rohwedder K, Kim SY, Lay-Flurrie J, Viswanathan P, McMurray JJV, Solomon SD. Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Feb 26;10(4):370-8. doi: 10.1001/jamacardio.2025.0016. Online ahead of print. PubMed 40009358 ↗
  • Butt JH, Jhund PS, Henderson AD, Claggett BL, Desai AS, Viswanathan P, Kolkhof P, Schloemer P, Amarante F, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV; FINEARTS-HF Committees and Investigators. Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial. Lancet Diabetes Endocrinol. 2025 Feb;13(2):107-118. doi: 10.1016/S2213-8587(24)00309-7. Epub 2025 Jan 13. PubMed 39818225 ↗
  • Butt JH, Henderson AD, Jhund PS, Claggett BL, Desai AS, Lay-Flurrie J, Viswanathan P, Lage A, Scheerer MF, Lam CSP, Senni M, Shah SJ, Voors AA, Bauersachs J, Fonseca C, Kosiborod MN, Linssen GCM, Petrie MC, Schou M, Verma S, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HF. J Am Coll Cardiol. 2025 Jan 21;85(2):140-155. doi: 10.1016/j.jacc.2024.10.111. Epub 2024 Dec 10. PubMed 39665701 ↗
  • Chimura M, Wang X, Jhund PS, Henderson AD, Claggett BL, Desai AS, Fonseca C, Goncalvesova E, Katova T, Mueller K, Glasauer A, Rohwedder K, Viswanathan P, Nodari S, Lam CSP, Saldarriaga CI, Senni M, Sharma K, Voors AA, Zannad F, Pitt B, Vardeny O, Vaduganathan M, Solomon SD, McMurray JJV. Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Jan 1;10(1):59-70. doi: 10.1001/jamacardio.2024.4613. PubMed 39550721 ↗
  • Vardeny O, Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Matsumoto S, Merkely B, Zieroth S, Yilmaz MB, Lay-Flurrie J, Viswanathan P, Horvat-Broecker A, Scalise A, McMurray JJV, Solomon SD. Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiol. 2025 Jan 1;10(1):42-48. doi: 10.1001/jamacardio.2024.4539. PubMed 39550716 ↗
  • Mc Causland FR, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, Henderson AD, Brinker M, Perkins R, Scheerer MF, Schloemer P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, McMurray JJV, Solomon SD. Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF Trial. J Am Coll Cardiol. 2025 Jan 21;85(2):159-168. doi: 10.1016/j.jacc.2024.10.091. Epub 2024 Oct 25. PubMed 39490700 ↗
  • Docherty KF, Henderson AD, Jhund PS, Claggett BL, Desai AS, Mueller K, Viswanathan P, Scalise A, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. Circulation. 2025 Jan 7;151(1):45-58. doi: 10.1161/CIRCULATIONAHA.124.072011. Epub 2024 Sep 29. PubMed 39342512 ↗
  • Vaduganathan M, Claggett BL, Kulac IJ, Miao ZM, Desai AS, Jhund PS, Henderson AD, Brinker M, Lay-Flurrie J, Viswanathan P, Scheerer MF, Lage A, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, McMurray JJV, Solomon SD. Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure. Circulation. 2025 Jan 14;151(2):149-158. doi: 10.1161/CIRCULATIONAHA.124.072055. Epub 2024 Sep 28. PubMed 39340828 ↗
  • Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Borentian M, Lay-Flurrie J, Viswanathan P, Behmenburg FU, McMurray JJV, Solomon SD. Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Feb 1;10(2):176-181. doi: 10.1001/jamacardio.2024.3782. PubMed 39332395 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in May 2024, 44 months.

Results were first posted in Aug 2025, 1 year 3 months after primary completion.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 44 months is above that.

Counting every sponsor, half of 151 studies reached it within 39 months; a quarter within 25 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2020
First posted
Jun 17, 2020
StartActual
Sep 14, 2020
Primary completionActual
May 15, 2024
CompletionActual
Jun 14, 2024
Results first posted
Aug 26, 2025
Last update
Aug 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04435626
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jun 17, 2020
Start date
Sep 14, 2020
Primary completion
May 15, 2024
Completion
Jun 14, 2024
Results posted
Aug 26, 2025
Last update
Aug 26, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion